1. GLP-1 Developer Kailera and Proteomics Firm Alamar File for U.S. IPOs, Signaling Biotech Market Thaw
Two biotech firms, GLP-1 drug developer Kailera and proteomics company Alamar, have filed for initial public offerings in the United States. This dual filing represents a notable test of investor appetite for life sciences companies, particularly in the high-profile GLP-1 weight-loss and diabetes drug space and the adj...